共 25 条
- [1] Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS421 - TPS421Ulahannan, Susanna VarkeyJohnson, Melissa LynneWeiss, Mia C.Vandross, Andrae L.Vidal-Cardenas, Sofia LuzSyed, MustafaTolcher, Anthony W.
- [2] Phase I study of the tissue factor-targeting antibody-drug conjugate XB002 among patients with advanced solid tumors (JEWEL-101): Design of expansion cohorts for endometrial, epithelial ovarian, and cervical cancersGYNECOLOGIC ONCOLOGY, 2024, 190 : S280 - S280Syed, MustafaTolcher, AnthonyJohnson, MelissaWeiss, MiaVandross, AndraeVidal-Cardenas, SofiaUlahannan, Susanna
- [3] Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS237 - TPS237Ulahannan, Susanna VarkeyJohnson, Melissa LynneWeiss, Mia C.Vandross, Andrae L.Vidal-Cardenas, Sofia LuzSyed, MustafaTolcher, Anthony W.
- [4] Phase I expansion study of the tissue factor (TF)etargeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)ANNALS OF ONCOLOGY, 2023, 34 : S1500 - S1501Ulahannan, S.Johnson, M. L.Weiss, M. C.Vandross, A.Vidal-Cardenas, S.Syed, M.Tolcher, A. W.
- [5] A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stageEUROPEAN JOURNAL OF CANCER, 2022, 174 : S92 - S93Ulahannan, S.Johnson, M. L.Park, H.Vandross, A.Uttamsingh, S.Li, J.Syed, M.Tolcher, A.
- [6] Phase 1 Study of the Tissue Factor Targeting Antibody-Drug Conjugate XBOO2 in Patients with Advanced Solid Tumors (JEWEL-101): Design of Expansion Cohorts for Squamous Cell Carcinoma of the Head and NeckINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E31 - E32Ulahannan, S.Johnson, M.Weiss, M.Vandross, A.Vidal-Cardenas, S.Syed, M.Tolcher, A.
- [7] Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancerCANCER RESEARCH, 2018, 78 (04)Modi, ShanuPusztai, LajosForero, AndresMita, MonicaMiller, Kathy D.Weise, AmyKrop, IanBurris, Howard, IIIKalinsky, KevinTsai, MichaelaLiu, Minetta C.Hurvitz, Sara A.Wilks, SharonAdemuyiwa, FolusoDiab, SamiHan, Hyo S.Kato, GiraldoNanda, RitaO'Shaughnessy, JoyceKostic, AnaLi, MarthaSpecht, Jennifer
- [8] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1815 - 1825Lemech, CharlotteWoodward, NatashaChan, NancyMortimer, JoanneNaumovski, LouieNuthalapati, SilpaTong, BoJiang, FangAnsell, PeterRatajczak, Christine K.Sachdev, Jasgit
- [9] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumorsInvestigational New Drugs, 2020, 38 : 1815 - 1825Charlotte LemechNatasha WoodwardNancy ChanJoanne MortimerLouie NaumovskiSilpa NuthalapatiBo TongFang JiangPeter AnsellChristine K. RatajczakJasgit Sachdev
- [10] Mifepristone (MIFE), a glucocorticoid receptor (GR) antagonist, in combination with eribulin (E) in advanced solid tumors: A phase 1 study with dose expansion in patients (pts) with triple-negative breast cancer (TNBC)JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Nanda, RitaWilks, SharonModiano, Manuel R.Spira, Alexander I.Becerra, CarlosWalling, JackieDat NguyenBaker, GabrielleConzen, Suzanne D.